Reported results
- Net sales were $74,000 for the quarter ended September 30, 2026.
- Gross profit was $40,000 for the quarter ended September 30, 2026.
- Research and development expenses were $0.1 million for the quarter ended September 30, 2026.
- Selling, general and administrative expenses were $2.8 million for the quarter ended September 30, 2026.
- Net loss was $2,821,000 for the quarter ended September 30, 2026.
- Cash, cash equivalents and restricted cash totaled $5.0 million as of September 30, 2026.
Guidance
- The Company expects to launch Tome Clearing Treatment in the first half of 2027.
- The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.
